LENVIMA® for first-line unresectable hepatocellular carcinoma

LENVIMA uHCC Video Library

HCP=health care provider; uHCC=unresectable hepatocellular carcinoma; REFLECT=A Multicenter Randomized, Open-Label, Phase 3 Trial to Compare the EFficacy and Safety of LEnvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With UnreseCtable HepaTocellular Carcinoma; OS=overall survival; PFS=progression-free survival; ORR=overall response rate; CP-A=Child-Pugh A; CP-B=Child-Pugh B.

Featured HCPs